Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Non-Current Deffered Revenue (2016 - 2017)

Historic Non-Current Deffered Revenue for Aptevo Therapeutics (APVO) over the last 3 years, with Q2 2017 value amounting to $2.8 million.

  • Aptevo Therapeutics' Non-Current Deffered Revenue fell 1628.74% to $2.8 million in Q2 2017 from the same period last year, while for Jun 2017 it was $2.8 million, marking a year-over-year decrease of 1628.74%. This contributed to the annual value of $2.9 million for FY2016, which is 1271.85% down from last year.
  • Aptevo Therapeutics' Non-Current Deffered Revenue amounted to $2.8 million in Q2 2017, which was down 1628.74% from $2.8 million recorded in Q1 2017.
  • Aptevo Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $3.3 million during Q2 2016, with a 5-year trough of $2.8 million in Q2 2017.
  • Over the past 3 years, Aptevo Therapeutics' median Non-Current Deffered Revenue value was $3.0 million (recorded in 2016), while the average stood at $3.0 million.
  • As far as peak fluctuations go, Aptevo Therapeutics' Non-Current Deffered Revenue tumbled by 1271.85% in 2016, and later tumbled by 1628.74% in 2017.
  • Aptevo Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $3.3 million in 2015, then dropped by 12.72% to $2.9 million in 2016, then fell by 3.45% to $2.8 million in 2017.
  • Its Non-Current Deffered Revenue stands at $2.8 million for Q2 2017, versus $2.8 million for Q1 2017 and $2.9 million for Q4 2016.